Table 1 Selection of source and study populations
From: Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
Total Population | |
|---|---|
Source Population | |
Patients aged ≥18 years with evidence of new myelosuppressive chemotherapy course from 1/2011 to 12/2015 | 643,676 |
plus ≥6 months continuous health benefits prior to chemotherapy course | 507,181 |
plus evidence of single primary solid tumor or NHL at the time of chemotherapy initiation | 359,727 |
plus no evidence of stem cell/bone marrow transplant prior to or during chemotherapy | 359,429 |
plus no evidence of thrombocytopenia prior to chemotherapy initiation | 352,571 |
plus no evidence of causes of secondary thrombocytopenia prior to or during the chemotherapy course | 332,512 |
Study Population | |
Receipt of chemotherapy regimen including one of the following drugs of interest | 215,508 |
Carboplatin | 59,381 |
Cisplatin | 18,380 |
Cyclophosphamide | 67,530 |
Fluorouracil | 10,408 |
Gemcitabine | 3704 |
Oxaliplatin | 5867 |
Vincristine | 766 |
≥ 2 Drugs of Interest | 49,472 |
Carboplatin+Fluorouracil | 343 |
Carboplatin+Gemcitabine | 1154 |
Cisplatin+Cyclophosphamide | 145 |
Cisplatin+Fluorouracil | 2462 |
Cisplatin+Gemcitabine | 1318 |
Cyclophosphamide+Fluorouracil | 2117 |
Cyclophosphamide+Vincristine | 13,812 |
Fluorouracil+Oxaliplatin | 27,566 |
Gemcitabine+Oxaliplatin | 363 |
Other Regimens | 192 |